1. Scrip
  2. >>Business
  3. >>Strategy

Regeneron Will Move Two Factor XI Agents Into Phase III

 
• By Joseph Haas

With successful Phase II data versus active comparators for both REGN7508 and REGN9933, Regeneron hopes to position the candidates to compete against existing factor X products.

Regeneron reports positive Phase II data for two factor XI anticoagulants • Source: Shutterstock

In a battle with Bristol Myers Squibb/Johnson & Johnson, Bayer and privately held Anthos to bring the first factor XI anticoagulant product to market, Regeneron reported on 19 December that its pair of factor XI-targeted antibodies succeeded in Phase II studies and are expected to advance into Phase III in 2025.

Key Takeaways
  • Regeneron plans to advance its two factor XI anticoagulant candidates into Phase III after reporting positive data from two Phase II trials.
  • REGN7508 demonstrated superiority versus enoxaparin and non-inferiority to apixaban, while REGN9933, which poses less bleeding risk than ‘7508, showed non-inferiority to enoxaparin

The Tarrytown, NY-based firm is developing REGN7508, which targets factor XI’s catalytic domain, and REGN9933, which acts on the A2 domain and is intended to present lower bleeding risk than ‘7508, to offer new therapeutic alternatives for patients at high risk of bleeding incidents and who are not viable candidates for currently available anticoagulant

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

A Short History Of MASH Deals, Culminating In GSK/Boston Pharma

 
• By Joseph Haas

Both high-profile failures and small investments that are yielding success so far characterize the dealmaking in MASH over the past 15 years or so.

Lupin CEO On Trump’s Most Favored Nation Policy, Tariffs, Firm’s Five-Year Plan

 
• By Vibha Ravi

Lupin CEO Vinita Gupta speaks on Trump’s Most Favored Nation Policy, the Inflation Reduction Act’s “pill penalty” and other developments in the US, a major market for the company, as she and MD Nilesh Gupta outline a five-year plan focused on complex generics and technology platforms

Novo Nordisk’s CEO Forced Out After Falling Behind In GLP-1 Battle

 
• By Andrew McConaghie

Company surprises investors with Jørgensen's exit but insists its strategy will not change.

Will Other Major MASH Deals Follow GSK/Boston Pharma?

 
• By Joseph Haas

GSK’s $1.2bn payout for Boston Pharma’s efimosfermin is the first billion-dollar-plus MASH deal in nearly nine years, but several other advanced MASH programs could be positioned for takeout.

More from Therapy Areas

Leo Roars To A Profit In Q1 As Adbry Grows In US

 
• By Kevin Grogan

The Danish firm's atopic dermatitis drug is holding its own despite strong competition from Sanofi/Regeneron’s Dupixent.

Multiple Launches Help Lilly’s Japan Growth

 
• By Ian Haydock

Lilly saw solid growth for its business in Japan last year on the back of several new launches and is building its obesity and Alzheimer's portfolios in the country.

Novo Nordisk Looks To Septerna For Oral Obesity Options

 
• By Mary Jo Laffler

Deal Snapshot: The Danish drugmaker is partnering with GPCR drug discovery expert Septerna to develop multiple small molecules for cardiometabolic targets.